KAHR

KAHR: KAHR is developing novel bi-functional fusion proteins that convert cancer defense signals into selective offense beacons for the immune system to attack.
The company lead product, DSP107, is a CD47-41BB targeting compound that simultaneously target cancer cells, weaken their innate defenses and activate an effective, local response of both innate (by blocking ‘Don’t eat me’ signals) and adaptive immunity (by providing co-stimulation signal to T and NK cells).
The company recently announced a clinical collaboration agreement with Roche on a phase I/II which is planned to commence in the US during Q3/2020 to study DSP107 monotherapy and in combination with Atezolizumab for solid tumor patients.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Asia
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Immuno-Oncology
Listing
Private
Website:
Profiles:
Address:
1 Kiryat Hadassah JBP Bldg.
Jerusalem, Yerushalayim POB 9779
Israel

Company Participants at Winter Private Company Showcase

Yaron Pereg, PhD
KAHR, CEO
Executive leader with over a decade of experience leading worldwide pre-clinical and clinical programs in oncology and immune-oncology. Heading multi-disciplinary teams and managing multi-million-dollar budgets in private and publicly traded companies. Prior to joining KAHR, served as Chief Development Officer at Cellect Biotechnology (APOP) and as Senior Director of Oncology at BioLineRx (BLRX). Prior to that held R&D positions at Genentech, a leading biotechnology company, member of the Roche Group.

Upcoming Company Event Participation